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Mouse strain-speciﬁc differences in the carbohydrate composition of intestinal mucins were hypothe-
sized to account for strain-dependent susceptibility to Entamoeba histolytica. To test this hypothesis,
intestinal mucins from susceptible and resistant inbred strains of mice were analyzed for their O-glycan
content and for their ability to inhibit amoebic adherence to (GalNAc)12–27-HSA neo-glycoproteins. The
results showed that the colorectal mucin O-glycan of susceptible CBA mice was lower in sialic acid con-
tent than that of resistant C57BL/6 and BALB/c mice. Mucins from CBA mice were more potent inhibitors
of E. histolytica adherence to neo-glycoproteins than were mucins from C57BL/6 or BALB/c mice. Consis-
tent with the role of terminal Gal/GalNAc as a receptor for amoebic adherence, sialidase treatment of
C57BL/6 and BALB/c colorectal mucins increased their ability to inhibit E. histolytica adherence to the
neo-glycoproteins. These results provide evidence of mouse strain-speciﬁc differences in the sialic acids
content of mucin O-glycans. These dissimilarities likely contribute to the differential susceptibility of the
three mouse strains to E. histolytica infection.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
The anaerobic parasitic protozoan Entamoeba histolytica (E. his-
tolytica) is estimated to infect about 1% of the world’s population
(about 50 million people), resulting in 40,000–100,000 deaths
annually. Transmission of the parasite is primarily through the fe-
cal-oral ingestion of cysts, which pass through the stomach to
reach the small intestine. There, excystment results in the release
of trophozoites, migration to the large intestine, and colonization
by adherence to the mucous layer. Attachment of the parasite to
the intestinal wall requires galactose (Gal)/N-acetylgalactosamine
(GalNAc) inhibitable lectins, speciﬁcally, their heavy subunits
(Hgls), which have been shown to bind the Gal and GalNAc resi-
dues exposed on the luminal surface of host mucins [1,2].Studies on mice have described strain-speciﬁc differences in
their susceptibility to E. histolytica, with resistance to infection
shown to be H-2 haplotype and lymphocyte independent [3,4].
Moreover, resistance to the parasite was observed even in IL-12,
IFN-c or iNOS deﬁcient mice of resistant mouse strains, thus ruling
out the involvement of the immunological compartment in resis-
tance, at least in the initial stage of E. histolytica infection. Since
E. histolytica parasitizes the large intestine and parasite Hgls are vi-
tal for host attachment and infection [2], we hypothesized that
strain-speciﬁc differences in mucus glycosylation in the large
intestine mediated susceptibility vs. resistance.
Mucin is a family of large glycoproteins whose function in-
cludes the protection of intestinal epithelial cells from physical
and physiological damage [5–9]. O-glycans attached to mucin pro-
tein backbones play an important role in mucin function. However,
despite their importance in disease resistance [10], differences in
the O-glycan structures of mucins among mouse strains have not
been investigated. Thus, in the present study, we compared the
O-glycomic proﬁles of large intestinal mucus from C57BL/6, CBA,
and BALB/c mice, known to differ in their susceptibility to E. his-
tolytica infection. The results showed that the afﬁnity of E. histoly-
tica toward mouse mucins is determined by the relative abundance
of sialic acids on their O-glycans and that differences in sialic acid
content may contribute to host susceptibility to the parasite.
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2.1. Ethics statement
Animal experiments conducted in the present study were ap-
proved by the Animal Care and Use Committee, Nagasaki Univer-
sity, and the experimental procedures were performed in
accordance with the Guidelines for Animal Experimentation estab-
lished by Nagasaki University (project number 1104190916).2.2. Isolation and semi-puriﬁcation of colorectal mucins from mice
C57BL/6J (B6) and CBA/J (CBA) mice (6- to 7-weeks-old, male)
were purchased from KBT Oriental Co., Ltd. (Saga, Japan) and
BALB/c (BALB) mice (6- to 6.5-weeks-old, male) were purchased
from Japan SLC, Inc. (Fukuoka, Japan). All animals were fed under
speciﬁc-pathogen-free (SPF) condition. Materials containing muc-
ins were prepared as described [11]. For each experiment, B6,
CBA and BALB mice (n = 5 for each strain) were sacriﬁced by
diethyl ether anesthesia and the colorectum was collected. The
luminal contents were removed and the tissues were rinsed with
ice-cold saline. Mucosal samples were obtained by scraping and
were immediately frozen at 80 C. The frozen mucosal samples
(150 mg, wet weight) were homogenized on ice in 1 ml of ice-cold
5 mM EDTA solution (pH 7) for 1 min using a Potter–Elvehjem
homogenizer. The homogenized samples were then treated with
50 ll of protease (P6110, Sigma) and incubated at 37 C for
80 min. The digested samples were left on ice for 10 min, after
which 3.5 ll of protease inhibitor cocktail (P8340, Sigma) was
added to each one. The samples were centrifuged at 10,000 rpm
for 60 min at 4 C. The mucin-containing supernatants were puri-
ﬁed on a Sepharose CL-4B (GE Healthcare) column equilibrated
with 0.2 M NaCl, applying 1 ml of each sample on a column con-
taining 8 ml of gel slurry and then eluting 0.6 ml fractions with
0.2 M NaCl. After removing aggregates by centrifuging at
10,000 rpm for 10 min at 4 C, aliquots (9 ll) of each fraction were
subjected to 4–12% Bis-Tris NuPAGE gels electrophoresis (Invitro-
gen). The mucin-containing fractions conﬁrmed by PAS staining
(Pierce glycoprotein staining kit, Thermo) were concentrated 20-
fold using an Amicon Ultracel-100 K (Millipore) and directly used
in binding inhibition assays or exchanged with 50 mM ammonium
bicarbonate (ABC) for glycoblotting. The samples obtained using
this protocol would contain the mixture of mucin species as de-
scribed previously [12].2.3. Glycoblotting-assisted glycomics of colorectal mucin from mice
A high-throughput method for glycan analyses of mucins was
performed as described previously [13]. This method releases both
O- and N-glycans from glycoproteins, although in this study only
O-glycans were analyzed. Brieﬂy, 80 ll of H2O, 5 ll of 1 M ABC,
and 5 ll of PNGase F (1 U/ll, Roche, IN) were added to 10 ll of con-
centrated samples, which were then incubated at 37 C for 24 h.
After the addition of 200 ll of 50 mM ABC, the samples were ap-
plied to YM-10 columns. The column was washed twice with
280 ll of 50 mM ABC by centrifugation at 12,000g for 25 min at
25 C. Flow-through fractions contained N-glycans, while the por-
tion of the supernatant remaining on the column consisted of O-
glycosylated proteins. The latter were concentrated to 25 ll, trea-
ted with 20–30 mg of ammonium carbamate (Tokyo Chemical
Industry Co., Ltd.), and incubated at 60 C for 20 h followed by
the addition of 500 ll of H2O and SpeedVac processing at high tem-
perature to remove ammonium carbamate. The residual material
was reconstituted in 25 ll of H2O, with 1 pmol of chitotetraose
(GN4, Seikagaku Biobusiness, Tokyo) added as an internalstandard. An aliquot of this solution was subject to glycoblotting
[13] using BlotGlyco H beads (50 ll) (10 mg/ml suspension, Sumi-
tomo Bakelite Co., Tokyo). On-bead methyl esteriﬁcation of sialic
acid carboxyl groups was carried out by incubating the samples
with 100 ll of 100 mM 3-methyl-1-p-tolyltriazene (MTT) in 1,4-
dioxane at 60 C to dryness, followed by three serial washes with
1,4-dioxane, MeOH, and H2O. The glycans bound to the beads were
subjected to transiminization by treating them with a mixture of
180 ll 2% acetic acid in MeCN and 20 ll of 5 mM Na-((amino-
oxy)acetyl)tryptophanylarginine methyl ester (aoWR) at 80 C to
dryness. Tagged glycans were eluted by the addition of 100 ll of
H2O and an aliquot was puriﬁed using a MassPREP HILIC plate
(Waters). Puriﬁed samples were directly mixed with DHB matrix
solution (10 mg/ml in 30% MeCN) and dried to afford crystals.
These were subjected to MALDI-TOF MS analysis on an Ultraﬂex
III TOF/TOF mass spectrometer (Bruker Daltonics) equipped with
a reﬂector and controlled by the FlexControl 3.3 software. The
masses of the precursor ions and fragment ions obtained in reﬂec-
tor mode were annotated using the FlexAnalysis 3.3 software. The
relative amounts of the O-glycans were quantiﬁed against 1 pmol
of internal standard. The glycans were structurally identiﬁed by
mass spectrometric analysis as well as by using the GlycoSuite
database (http://glycosuitedb.expasy.org/glycosuite/glycodb). All
experiments were done at least twice and the data obtained were
consistent and reproducible among the experiments.
2.4. Preparation of E. histolytica membranes
E. histolytica HM1:IMSS trophozoites were cultured in TYI-S-33
medium supplemented with 15% adult bovine serum (GemCell),
2.2% vitamin mix (Sigma), and penicillin/streptomycin (PenStrep,
Gibco). Sub-conﬂuent cultures of the parasites were harvested
and the trophozoites were washed twice with wash buffer
(75 mM Tris–HCl, pH 7.2, with 65 mM NaCl) at 200g for 5 min
at 4 C, after which a 9-fold volume of osmotic lysis buffer
(10 mM Na-phosphate (pH 8.0) with protease inhibitor (EDTA-
free) and 5 mM EDTA) was added to the pellet. The mixture was
incubate for 5 min at 37 C followed by resuspension of the pellet
(0.5 ml) in 4.5 ml of osmotic lysis buffer and a second incubation at
37 C for 5 min. The lysed samples were sonicated on ice using a
BRANSON Soniﬁer sonicator until the parasite particles could no
longer be detected by light microscopy. The sample was centri-
fuged at 50,000g for 1 h at 4 C and the resulting pellet was resus-
pended in 5 ml of osmotic lysis buffer, followed by centrifugation
at 100,000g for 1 h at 4 C. The pellet was suspended again in
1 ml of osmotic lysis buffer and used as E. histolytica membranes
in subsequent experiments. The presence of Hgls in the isolated
membranes was conﬁrmed by Western blotting using an anti-Hgl
antibody (7F4).
2.5. Binding inhibition assay using neo-glycoproteins, E. histolytica
membranes, and mouse-derived mucins
Sialidase from Vibrio cholerae (Roche) was used as an active or
heat-inactivated (at 80 C for 30 min) enzyme. Mucins from the
colorectum of B6, CBA, and BALB mice were incubated at 37 C
overnight with 0.33 ll of the enzyme (active or inactivated) per
reaction in a total reaction mixture volume of 2 ll (adjusted with
0.2 M NaCl). Reactions without mucins were prepared as control
samples. All samples were incubated at 80 C for 30 min, mixed
with 100 ll of 50-fold diluted E. histolytica membranes, and incu-
bated at 4 C overnight with rotation. (GalNAc)12–27-HSA (Tn Anti-
gen-HSA) was purchased (DEXTRA Laboratories, UK) and coated on
96-well plates (NUNC, Denmark) at 10 pmol/100 ll/well at 4 C
overnight. The plate was washed three times with TBST and the
incubated samples were loaded onto the plate, which was kept
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times with TBST followed by the addition of 100 ll of 1:5000 di-
luted HRP-7F4 (2.56 mg/ml, Techlab, USA) to each well and incuba-
tion at 4 C overnight. Finally, the plate was washed three times
with TBST and incubated with 100 ll of 1-Step™ Ultra TMB-ELISA
solution (Thermo)/well at room temperature for 15 min. The reac-
tions were stopped by the addition of 50 ll of 1 M sulfuric acid/
well and absorbance at 450 nm (A450) was subsequently detected
using a Labsystems Multiskan MS plate reader. The percentages
of binding inhibition were calculated as: binding inhibition
(%) = [(A450 of sample without mucin)  (A450 of sample with mu-
cin)]/(A450 of sample without mucin)  100. Mucins treated with
active or inactivated sialidase were compared, with the average
of six independent results per group expressed as scatter plots.2.6. Statistical analysis
In binding inhibition studies, six independent experiments per
group were conducted. The Mann–Whitney U-test was applied in
comparisons of the active-sialidase-treated and inactivated-siali-
dase-treated groups.3. Results
3.1. O-glycomics of mucin derived from B6, CBA, and BALB mice as
determined by the ammonium carbamate method
After obtaining the mucin samples from B6, CBA, and BALB
mice, the O-glycomic proﬁles of the three mouse strains were com-
pared. O-glycans were liberated from the mucin samples using
ammonium carbamate, and then puriﬁed and labeled with aoWR
tag using the glycoblotting technique [13–15]. After the removal
of excess reagent, the labeled glycans were analyzed by MALDI-
TOF MS. As shown in Fig. 1, N-glycans not cleaved completely by
PNGase F were also released (signals shown with asterisks) by this
method, but they were not studied further. These N-glycan derived
peaks were also observed when the ﬂow-through fractions of PNG-
ase F-treated samples were analyzed by MALDI-TOF MS (data not
shown). Fairly similar O-glycan proﬁles were observed among
the three mice strains, with the greatest similarity between B6
and BALB samples (Fig. 1). At least 30 types of O-glycans were de-
tected (Table 1), 17 of which were neutral while the rest were
acidic. O-glycans that differed in their expression proﬁle between
the E. histolytica susceptible strain (CBA) and the resistant strains
(B6 and BALB) include O-glycans which possess sialic acid residues
(Table 1 and Fig. 2). There were no signiﬁcant differences in the rel-
ative intensities of the deduced neutral O-glycans among the sam-
ples (Fig. 2A), whereas, in general, the expression of sialylated O-
glycans tended to be lower in CBA mice than in B6 and BALB mice.
Speciﬁcally, the expression levels of all identiﬁed sialylated O-gly-
cans, except for Nos. 15 and 29, were 2- to 5-fold higher in B6 and
BALB mice than in CBA mice (Fig. 2B). To conﬁrm that each peak
obtained by MALDI-TOF MS analyses truly reﬂected the deduced
composition of acidic O-glycans, each of the glycans was further
fragmented using LIFT TOF/TOF MS mode (Ultraﬂex III, Bruker)
and the resulting fragments were then annotated with the Flex-
Analysis 3.3 program. Among the 13 types of deduced acidic O-gly-
cans, nine were conﬁrmed to have NeuAc, as determined by MS/MS
analyses. A typical spectrum obtained in MS/MS analyses of Neu-
Ac-containing O-glycans involves the 305 Da peak (correspond-
ing to a loss of the terminal NeuAc(OMe) from the precursor ion
peak), which can be easily detected (Supplemental Fig. 1). The
MS/MS spectra for the other four types of deduced sialylated O-gly-
cans were obtained but could not be analyzed because of excess
noise.3.2. Binding inhibition assay with sialidase-treated mucins
To assess the role of sialic acids of mucin O-glycans in the
attachment of E. histolytica to mouse intestinal mucins, binding
inhibition assays using (GalNAc)12–27-HSA coated microtiter plates
were conducted, as shown in Fig. 3A. The assay is based on the
binding of Hgls on the E. histolytica membrane to GalNAc of (Gal-
NAc)12–27-HSA in the absence of mucins or in the presence of un-
treated mucin in which the sugars have been masked by sialic
acids. However, if the Gal and GalNAc sugars on these mucins
are exposed by sialidase treatment, they compete with Hgl binding
and interfere with this association. If the mucins contain low levels
of sialic acids, there will be no difference between the addition of
sialidase-treated mucin and the control mucin treated with heat-
inactivated sialidase. Thus, to conﬁrm the role of sialic acids in par-
asite attachment, the samples were treated with sialidase before
their inclusion in the inhibition assay (Fig. 3). The amounts of mu-
cin used in this study were converted to and expressed as ‘‘Starting
mucus amount (mg, wet weight)’’ because quantiﬁcation of mucins
is difﬁcult using traditional protocols for quantifying protein con-
centrations due to the high density of O-glycans attached to mucin
molecules. For B6 mucins, the results showed slight, but not signif-
icant, differences in sialidase (+SA)- vs. inactivated sialidase (SA)-
treated mucins (Fig. 3B), indicating that sialic acid of B6 mucin
inhibits E. histolytica membrane binding to some extent. For CBA
mucins, there was no difference in the ability of sialidase- and
inactivated-sialidase-treated CBA mucins to compete with Hgl
binding to (GalNAc)12–27-HSA (Fig. 3C). This observation suggested
that CBA mucins contain relatively few sialic acids, in agreement
with the results obtained by MALDI-TOF MS/MS analysis (Figs. 1
and 2). As predicted, but nonetheless surprising, sialidase-treated
BALB mucins exhibited signiﬁcantly higher binding inhibition than
inactivated-sialidase-treated BALB mucins, both at lower (0.8 mg
of mucus) and higher (1.7 mg of mucus) amount of mucin. Strik-
ingly, in some experiments, inactivated-sialidase-treated BALB
mucins enhanced E. histolytica membrane binding to (GalNAc)12–
27-HSA, suggesting their strong inhibitory potential (Fig. 3D). These
observations are in good agreement with the above-described re-
sults of the glycomic analysis.4. Discussion
The most important ﬁnding of this work was the differences in
the sialic acids content of large intestinal mucins among the three
strains of mice tested, as it can, at least in part, explain the ob-
served differential susceptibilities to E. histolytica infection. Our re-
sults are consistent with those reported by Asgharpour et al. [3],
who found that E. histolytica persisted in the large intestine of
CBA mice for more than 30 days after infection while the parasite
was cleared 4 days after the infection of B6 mice. Houpt et al. also
reported that BALB mice were resistant to E. histolytica infection [4]
and that their resistance was H-2 haplotype and lymphocyte inde-
pendent. Since Hgls are crucial for E. histolytica infection, these ear-
lier ﬁndings led us to examine the role of host mucin O-glycans as
the basis for the different murine susceptibilities.
Indeed, the sialic acids content of mucins isolated from the large
intestines of B6 and BALB mice were higher than those isolated
from CBA mice (Fig. 2). This observation suggested that the greater
attachment of E. histolytica to the large intestinal mucus of CBA
mice is due to the higher afﬁnity of Hgl for Gal/GalNAc (neutral
sugars) than for acidic sugars [16]. It would also explain the para-
site’s ability to remain for more than 30 days post-infection in the
large intestine of CBA mice but not in the intestines of B6 or BALB
mice [3,4]. To conﬁrm this hypothesis, we conducted a binding
inhibition assay using a neo-glycoprotein, E. histolytica membrane,
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Fig. 1. O-glycan analyses of colorectal glycoproteins from B6, CBA, and BALB mice. MALDI-TOF MS chart (m/z = 1100–2100) of ammonium–carbamate-released O-glycans.
The numbers on the top of each chart correlate with the O-glycans shown in Table 1. Asterisks indicate N-glycans remaining on mucins even after PNGase F treatment but
released after ammonium carbamate treatment, and hash signs indicate the contaminated hexose oligomers. I.S. indicates internal standard (GN4).
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showed that mucin derived from resistant BALB mice could not in-
hibit E. histolytica membrane binding to a neo-glycoprotein,
whereas inhibition was increased when the mucin was ﬁrst treated
with sialidase (Fig. 3D). On the other hand, regardless of sialidase
treatment, CBA mucin was able to inhibit E. histolytica membrane
binding to (GalNAc)12–27-HSA, suggesting that it did not contain a
large amount of sialic acids (Fig. 3C). However, glycans from BALB
and B6 while having similar sialic acid content/structures (Fig. 2)
behave differently in the binding assay (Fig. 3B and D). This might
be because the sites and density of O-glycans having sialic acids on
the mucins differ between these two mouse strains and the reason
why the parasites persisted in B6 mice for 4 days but BALB mice
were completely resistant to this infection. Further study needs
to be done to clarify this possibility in the future. The presence of
sulfation on colonic mucin O-glycans might be also important forthe resistance, even though we could not detect sulfated O-glycans
in this study probably because the amount of those glycans were
very few, as previously observed for human colonic MUC2 [17].
The expression patterns of colorectal mucus O-glycans were
mouse strain-speciﬁc (Figs. 1 and 2), with an abundance of cer-
tain acidic O-glycans detected on B6 and BALB colorectal mucins
but not on CBA mucins. Thus, seven sialylated O-glycans were
more highly expressed in the colorectal mucins of B6 and BALB
mice than in those of CBA mice (Fig. 2B). All the deduced struc-
tures in Table 1, except HexNAc4NeuAc2, have been published
previously or are available in the GlycoSuite database [18,19]
(http://glycosuitedb.expasy.org/glycosuite/glycodb). The differen-
tial O-glycans expression observed among the three investigated
mouse strains might reﬂect differences in the expression levels
and patterns of glycosyltransferases in the organs responsible
for generating these compounds, including sialyltransferases in
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Table 1
Deduced composition of O-glycans.
Number Mass (m/
z)
Deduced composition of O-glycan
1 1118 Hex1HexNAc1NeuAc1
2 1121 Hex2HexNAc1DeoxyHex1
3 1162 Hex1HexNAc2DeoxyHex1
4 1178 Hex2HexNAc2
5 1203 HexNAc3DeoxyHex1
6 1219 Hex1HexNAc3
7 1280 Hex2HexNAc1NeuAc1/
Hex1HexNAc1DeoxyHex1NeuGc1
8 1321 Hex1HexNAc2NeuAc1
9 1324 Hex2HexNAc2DeoxyHex1
10 1365 Hex1HexNAc3DeoxyHex1
11 1381 Hex2HexNAc3
12 1422 Hex1HexNAc4
13 1470 Hex2HexNAc2DeoxyHex2
14 1483 Hex2HexNAc2NeuAc1
15 1524 Hex1HexNAc3NeuAc1
16 1527 Hex2HexNAc3DeoxyHex1
17 1565 HexNAc4NeuAc1
18 1585 Hex2HexNAc4
19 1626 Hex1HexNAc2NeuAc2
20 1629 Hex2HexNAc2DeoxyHex1NeuAc1
21 1673 Hex2HexNAc3DeoxyHex2
22 1686 Hex2HexNAc3NeuAc1
23 1689 Hex3HexNAc3DeoxyHex1
24 1730 Hex2HexNAc4DeoxyHex1
25 1746 Hex3HexNAc4
26 1788 Hex2HexNAc2NeuAc2
27 1832 Hex3HexNAc3DeoxyHex2
28 1870 HexNAc4NeuAc2
29 1889 Hex2HexNAc4NeuAc1
30 1991 Hex2HexNAc3NeuAc2
256 K. Kato et al. / Biochemical and Biophysical Research Communications 436 (2013) 252–258the mouse large intestine. Support for this possibility comes from
a study of UDP-GalNAc: polypeptide N-acetylgalactosa-
minyltransferases, one of the glycosyltransferase families respon-
sible for mucin O-glycosylation, in which different expression pat-
terns were determined in the kidneys of the examined mouse
strains [20]. So far, 20 isoforms of mouse sialyltransferases have
been reported [21]. It will be of interest in the future to test
which sialyltranseferase is responsible for determining the sus-
ceptibility of the mice to E. histolytica.
In conclusion, in colorectal mucin samples, the proﬁles of O-
glycans, and especially of those containing sialic acid, differed
among B6, CBA, and BALB mice. The susceptibilities of those
mice to E. histolytica infection may thus be determined by the
expression levels of sialylated O-glycans, as measured in the E.
histolytica lectin binding inhibition assay conducted in this study.
Our results contribute to explaining some of the differences in
the outcomes of E. histolytica infection studies in mice and to a
better understanding of the basis of infectious diseases.Funding
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Fig. 3. Entamoeba histolyticamembrane binding inhibition assay using a neo-glycoprotein. (A) Schema of the inhibition assay. (B) B6 mucins treated with sialidase [B6 (+SA)]
or heat-inactivated sialidase [B6 (-SA)] were incubated with E. histolytica membranes and loaded onto a (GalNAc)12–27-HSA-coated microtiter plate. Six independent
experiments were conducted for each condition. The results are shown as a scatter plot with standard deviations. The results obtained with (C) CBA mucins and (D) BALB
mucins. Asterisks indicate signiﬁcant differences between sialidase- and inactivated-sialidase-treated BALB mucins, as determined in a Mann–Whitney’s U-test (⁄p < 0.05,
⁄⁄p < 0.01).
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